Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnostic performance and clinical feasibility of a novel one-step RT-qPCR assay for simultaneous detection of multiple severe acute respiratory syndrome coronaviruses.
Le TB, Kim HK, Ahn MJ, Zanin M, Lo VT, Ling S, Jiang Z, Kang JA, Bae PK, Kim YS, Kim S, Wong SS, Jeong DG, Yoon SW. Le TB, et al. Among authors: ahn mj. Arch Virol. 2022 Mar;167(3):871-879. doi: 10.1007/s00705-022-05383-0. Epub 2022 Feb 9. Arch Virol. 2022. PMID: 35137250 Free PMC article.
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).
Park S, Baldry R, Jung HA, Sun JM, Lee SH, Ahn JS, Kim YJ, Lee Y, Kim DW, Kim SW, Lee KH, Lee WJ, Choi JW, Chong K, Lee JI, Gwon SH, Son NH, Ahn MJ. Park S, et al. Among authors: ahn mj. J Clin Oncol. 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708. Online ahead of print. J Clin Oncol. 2024. PMID: 38828959
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. Among authors: ahn mj. N Engl J Med. 2024 Jun 2. doi: 10.1056/NEJMoa2402614. Online ahead of print. N Engl J Med. 2024. PMID: 38828946
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V. Prenen H, et al. Among authors: ahn mj. Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677. Online ahead of print. Clin Cancer Res. 2024. PMID: 38709220
736 results